Q-omics provides the consensus-scored ZNRD2 profile across patient tissues and cancer cell-line models. ZNRD2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNRD2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNRD2 RNA expression shows 19,257 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where ZNRD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNRD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNRD2 survival associations across molecular data types. ZNRD2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNRD2 RNA expression–survival associations across cancer types. High ZNRD2 expression shows unfavorable associations in ACC, HNSC, KICH, LIHC, TGCT and PRAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNRD2 RNA expression.
This table summarizes ZNRD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNRD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNRD2 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, LUSC and LUAD. The HNSC box plot shows higher ZNRD2 RNA expression in tumor versus normal tissue (log2 FC = +1.101, t-test p < 0.001).
This table shows molecular features associated with ZNRD2 in patient tissues and cancer cell lines. In patient samples, ZNRD2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNRD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
